10.7 C
London
Sunday, February 23, 2025
HomeMarketsEurope Markets

Europe Markets

spot_img

Xaluprine (previously Mercaptopurine Nova Laboratories)

OverviewThis is a summary of the European public assessment report (EPAR) for Xaluprine. It explains how the Committee for Medicinal Products for Human...

Ruxience | European Medicines Agency (EMA)

OverviewRuxience is a medicine used to treat the following blood cancers and inflammatory conditions:• follicular lymphoma and diffuse large B cell non-Hodgkin’s lymphoma...

Nimenrix | European Medicines Agency (EMA)

OverviewNimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by...

Tabrecta | European Medicines Agency (EMA)

OverviewTabrecta is a medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC), when the cancer...

Veoza | European Medicines Agency (EMA)

OverviewVeoza is a medicine used to treat moderate to severe vasomotor symptoms (also referred to as hot flushes or night sweats) associated with...

Ambrisentan Viatris (previously Ambrisentan Mylan)

OverviewAmbrisentan Viatris is a medicine that is used alone or combined with other medicines to treat adults with pulmonary arterial hypertension (PAH).PAH is abnormally...

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 February 2025

At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities, which cover all aspects of the risk management...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img